Cardiometabolic
Obesity Is Costing Europe Beyond the Clinic. A New Report Puts a Price on It
An Office of Health Economics analysis estimates that elevated BMI accounts for an economic burden equivalent to roughly 0.7% to 1.4% of national economic output across eight European countries. Healthcare spending is only part of the calculation.
Same country, different risks: why Iranian women’s heart disease profiles expose a blind spot in prevention policy
Menopause is a cardiometabolic checkpoint. Health systems still treat it like a hormone debate
GLP-1 drug choice now affects cardiovascular outcomes. Access and reimbursement rules have not caught up
MENA’s cardiometabolic crisis is a stability issue
Corxel’s oral GLP-1 trial adds momentum. The real question is who these drugs will reach
Half of CKM patients go untreated and most fail control
Sleep is now cardiovascular prevention. Health systems still treat it like lifestyle advice
The GLP-1 boom still needs exercise policy
Pharmacists are becoming the front door for cardiometabolic care. Policy is still treating them like the back office
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.
Diseases in Cardiometabolic
Explore disease data and country profiles on the IPM Alliance platform.
Explore diseases